BNP Paribas Financial Markets’s Fennec Pharmaceuticals FENC Stock Holding History

BNP Paribas Financial Markets’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$395K	Buy	36,727 +30,530	+493%	+$249K	﹤0.01%	3884
2026 Q1	$38.1K	Buy	6,197 +1,146	+23%	+$8.85K	﹤0.01%	4838
2025 Q4	$38.9K	Buy	5,051 +543	+12%	+$4.46K	﹤0.01%	4792
2025 Q3	$42.2K	Buy	4,508 +1,983	+79%	+$17.2K	﹤0.01%	4669
2025 Q2	$21K	Sell	2,525 -38,489	-94%	-$263K	﹤0.01%	4583
2025 Q1	$250K	Sell	41,014 -3,612	-8%	-$23.2K	﹤0.01%	3588
2024 Q4	$282K	Buy	44,626 +4,610	+12%	+$23.6K	﹤0.01%	3673
2024 Q3	$200K	Sell	40,016 -6,894	-15%	-$39.9K	﹤0.01%	3258
2024 Q2	$287K	Buy	46,910 +14,141	+43%	+$117K	﹤0.01%	2951
2024 Q1	$364K	Buy	32,769 +13,223	+68%	+$133K	﹤0.01%	3011
2023 Q4	$219K	Buy	19,546 +3,031	+18%	+$25.1K	﹤0.01%	3169
2023 Q3	$124K	Buy	16,515 +11,624	+238%	+$94.6K	﹤0.01%	3269
2023 Q2	$43.2K	Buy	4,891 +4,721	+2,777%	+$39.3K	﹤0.01%	3507
2023 Q1	$1.41K	Hold	170	–	–	﹤0.01%	3658
2022 Q4	$1.63K	Hold	170	–	–	﹤0.01%	3754
2022 Q3	$1.38K	Hold	170	–	–	﹤0.01%	4390
2022 Q2	$949	Sell	170 -3,286	-95%	-$19.1K	﹤0.01%	3910
2022 Q1	$19.4K	Buy	3,456 +3,224	+1,390%	+$16.2K	﹤0.01%	3732
2021 Q4	$1.02K	Sell	232 -24	-9%	-$179	﹤0.01%	4052
2021 Q3	$2.41K	Sell	256 -128	-33%	-$960	﹤0.01%	3777
2021 Q2	$2.8K	Sell	384 -2,412	-86%	-$16.1K	﹤0.01%	3845
2021 Q1	$17.4K	Sell	2,796 -1,420	-34%	-$10.7K	﹤0.01%	3780
2020 Q4	$31.4K	Sell	4,216 -997	-19%	-$7.59K	﹤0.01%	3737
2020 Q3	$31.6K	Buy	5,213 +4,404	+544%	+$31K	﹤0.01%	3668
2020 Q2	$6.75K	Buy	809 +747	+1,205%	+$5.55K	﹤0.01%	3882
2020 Q1	$368	Hold	62	–	–	﹤0.01%	4157
2019 Q4	$402	Sell	62 -1,354	-96%	-$7.27K	﹤0.01%	4266
2019 Q3	$6.81K	Hold	1,416	–	–	﹤0.01%	4223
2019 Q2	$5.66K	Sell	1,416 -1,244	-47%	-$5.27K	﹤0.01%	4225
2019 Q1	$12.9K	Buy	2,660 +2,465	+1,264%	+$16.2K	﹤0.01%	3992
2018 Q4	$1.24K	Sell	195 -175	-47%	-$1.22K	﹤0.01%	3894
2018 Q3	$3.03K	Hold	370	–	–	﹤0.01%	4198
2018 Q2	$3.86K	Buy	+370	New	+$4.39K	﹤0.01%	4159

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BNP Paribas Financial Markets's FENC Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Fennec Pharmaceuticals (FENC) stake by 493% in Q2 2026, buying an estimated $249K and bringing the position to 36,727 shares worth $395K. The position accounts for ﹤0.01% of the portfolio, ranked #3884.

BNP Paribas Financial Markets first reported a position in FENC in Q2 2018 and has held it in 33 quarters since. 98 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

BNP Paribas Financial Markets held 36,727 shares of Fennec Pharmaceuticals worth $395K as of Q2 2026.
BNP Paribas Financial Markets bought 30,530 Fennec Pharmaceuticals shares in Q2 2026, an estimated $249K.
Fennec Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3884 holding.
BNP Paribas Financial Markets first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
98 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.